Phorbol myristate acetate-induced Egr-1 expression is suppressed by phospholipase D isozymes in human glioma cells  by Ahn, Bong-Hyun et al.
FEBS Letters 581 (2007) 5940–5944Phorbol myristate acetate-induced Egr-1 expression is suppressed
by phospholipase D isozymes in human glioma cells
Bong-Hyun Ahna,1, Mi Hee Parkb,1, Young Han Leec, Do Sik Mina,*
a Cardiovascular Branch National Heart, Lung and Blood Institute (NHLBI), NIH Bldg 10/CRC 5-3288, 10 Center Drive, Bethesda, MD 20892, USA
b Department of Molecular Biology, College of Natural Science, Pusan National University, 30 Jangjeon dong, Geumjeong gu,
Busan 609-735, Republic of Korea
c Department of Biomedical Science and Technology, Institute of Biomedical Science and Technology (IBST),
Konkuk University, Seoul, Republic of Korea
Received 10 October 2007; revised 25 November 2007; accepted 27 November 2007
Available online 5 December 2007
Edited by Veli-Pekka LehtoAbstract Early growth response-1 (Egr-1) is involved in the
regulation of cell growth. Here, we found that overexpression
of phospholipase D (PLD) isozymes decreased tumor promoter
phorbol myristate acetate (PMA)-induced Egr-1 expression
and transactivation in glioma cells. Suppression of PMA-induced
Egr-1 was dependent on the expression level of PLD isozymes.
Overexpression of catalytically inactive PLD, treatment with
PA, and prevention of PA dephosphorylation by 1-propranolol
signiﬁcantly suppressed PMA-induced Egr-1 expression. PLD-
induced suppression of Egr-1 was reversed by inhibition of phos-
phatidylinositol 3-kinase (PI3K). Taken together, these results
suggest that elevated expression and activity of PLD attenuate
PMA-induced Egr-1 expression via PI3K pathway.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Glioma; Phospholipse D; PMA; Egr-1; PI3K1. Introduction
Transcription factor early growth response factor-1 (Egr-1)
is involved in the regulation of cell growth in response to mit-
ogens [1]. The fact that phorbol myristate acetate (PMA) stim-
ulated Egr-1 biosynthesis [2] was in agreement with function of
Egr-1 in cell growth. However, in other circumstances, Egr-1 is
induced very early in the apoptotic process [3]. Egr-1 has been
found to be decreased in several tumors [4–6]. It was suggested
that functional loss of Egr-1 may contribute to tumorigenic
potential [7]. Despite progress in characterizing the signaling
that positively regulate the Egr-1 gene expression, much less
is known about negative regulatory mechanism responsible
for loss of Egr-1 expression.
Phospholipase D (PLD), which catalyzes the hydrolysis of
phosphatidylcholine to phosphatidic acid (PA) and choline,
has been implicated in the generation of survival signals. There*Corresponding author. Address: Department of Molecular Biology,
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doi:10.1016/j.febslet.2007.11.077are two PLD isoforms, PLD1 and PLD2 which are regulated
by PKC and small G proteins [8]. PLD is overexpressed in hu-
man cancers [8] and prevent etoposide-induced apoptosis by
suppression of the expression of Egr-1 [9].
Malignant glioma, are refractory to classical chemotherapy
and radiotherapy and have a poor prognosis [10]. Egr-1
expression is signiﬁcantly down-regulated in human glioma tis-
sues compared with normal brain [6].
To investigate the signaling mechanism for altered expres-
sion of Egr-1, we examined whether PLD-mediated signaling
aﬀects PMA-induced Egr-1 expression in glioma cells. In the
present study, we demonstrate for the ﬁrst time that PMA-in-
duced Egr-1 expression is suppressed by elevated expression of
PLD in glioma cells.2. Materials and methods
2.1. Materials
Dual luciferase assay kits were from Promega (Madison, WI). The
antibodies to Egr-1 was from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Polyclonal antibody that recognizes both PLD1 and
PLD2 was generated as previously described [11]. Anti-b-tubulin anti-
body and phosphatidic acid were from Sigma (St. Louis, MO), and
various inhibitors were from Biomol (Plymouth Meeting, PA).
2.2. Construction of plasmids
The pEBS14luc construct was generously provided by Dr. Seung
Joon Baek (University of Tennessee, USA). The Egr-1 promoter repor-
ter construction (p-668egrLuc inserted into a pGL2-basic luciferase
plasmid) has been described [9].
2.3. Cell culture and transfections
U87 MG human astroglioma was obtained from the American Type
Culture Collection (Rockville, MD) and maintained in DMEM sup-
plemented with 10% (v/v) fetal bovine serum. U87 cells were tran-
siently transfected with expression plasmid using LipofectAMINE
Plus (Invitrogen) according to manufacturers instructions. U87 cells
overexpressing stably wild type PLD isozyme were obtained by trans-
fection.
2.4. PLD activity assay
PLD activity was assessed by measuring the formation of [3H] phos-
phatidylbutanol (PtdBut), the product of PLD-mediated transphos-
phatidylation, in the presence of 1-butanol. After 20 h transfection,
U87 cells in 6-well plates were serum-starved in the presence of
2 lCi/ml [3H] myristic acid for overnight. The cells were preincubated
with 0.3% 1-butanol for 10 min and then treated with agonist. The
extraction and characterization of lipids by thin-layer chromatography
were performed as previously described [9].blished by Elsevier B.V. All rights reserved.
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Cell extracts were separated in 8% SDS–polyacrylamide gel and the
proteins were blotted onto a nitrocellulose membrane. Subsequently,
membranes were incubated with speciﬁc antibodies. Antigen–antibody
complexes were visualized after incubating the membrane with horse-
radish peroxidase-conjugated secondary antibody and detected by en-
hanced chemiluminescence.
2.6. Luciferase assay
After 24 h of transfection with pGL2-Egr-1, the cells were treated
with PMA for 12 h. The activities of ﬁreﬂy and Renilla luciferase in
the cellular extracts were measured using the dual-luciferase reporter
assay system. Relative luciferase activity was obtained by normalizing
the ﬁreﬂy luciferase activity against the internal control Renilla lucifer-
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3.1. PMA-induced Egr-1 expression is suppressed by elevated
expression of PLD isozymes in glioma cells
Egr-1 expression is suppressed in astrocytic tumors com-
pared with normal brain tissue and loss of Egr-1 expression
may provide an important maker of glial cell malignancy
[12]. Since PLD is elevated in human cancer tissues [8], the role
of PLD in regulating expression of Egr-1 was examined. To
investigate whether Egr-1 is down-regulated by PLD in glioma
cells, we established U87 MG human glioma cells expressing
PLD1 and PLD2. Egr-1 protein level peaked 30 min after
PMA stimulation and declined thereafter (Fig. 1). A signiﬁcant
decline in Egr-1 protein level was observed by elevated expres-
sion of PLD isozyms compared with control cells. Three diﬀer-Blot: Egr-1
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Fig. 1. Elevated expression of PLD isozymes suppresses PMA-induced
Egr-1 expression in U87 MG glioma cells. Upper panel: expression of
PLD isozymes in glioma cells overexpressing PLD isozymes. Lower
panel: the glioma cells were stimulated with 100 nM of PMA for the
indicated time. The cell lysates were analyzed by immunoblotting with
the indicated antibodies. The data shown are representative of three
independent experiments.ent U87-PLD isozyme clones showing diﬀerent expression
level of PLDs were used to eliminate the possibility of random
gene aberrations during the transfection procedure. PMA-
induced Egr-1 expression was inversely correlated with
expression level of PLD isozymes (Fig. 2A). Moreover,
PMA-induced Egr-1 promoter activity was decreased by
elevated expression of PLD isozymes (Fig. 2B). These results
suggest that elevated protein expression of PLD isozymes isV
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Fig. 2. Down-regulation of Egr-1 in glioma cells expressing diﬀerent
level of PLD isozymes. (A) Upper panel: expression of PLD in glioma
cell clones overexpressing diﬀerent level of PLD isozymes. V (vector),
P1-W or P2-W (PLD1 or 2-weak expression), P1-M or P20M (PLD1
or 2-middle expression), P1-S or P2-S (PLD1 or 2-strong expression),
Lower panel: serum-starved cells expressing diﬀerent levels of PLD
isozymes were treated with 100 nM PMA for 1 h. The cell lysates were
analyzed by Western blot using the indicated antibodies. The data
shown are representative of three independent experiments. (B) After
24 h of transfection with Egr-1 promoter, the cells were treated with
PMA for 12 h, and luciferase activity was measured. Results show
means ± S.D. of three independent experiments.
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sion at transcriptional and post-transcriptional levels.
3.2. Elevated expression of PLD suppresses PMA-induced
transactivation of a reporter with Egr-1 response elements
The transactivation of Egr-1 in PMA-treated cells was deter-
mined using an Egr-1-responsive reporter. The plasmid pEB-
S14luc contained four copies of Egr-1 response elements
linked to the basal promoter, followed by a luciferase reporter
gene [13]. PMA-induced transactivation of Egr-1 was sup-
pressed by elevated expression of PLD isozymes (Fig. 3), sug-
gesting that PLD isozymes are involved in the suppression of
PMA-stimulated transactivation of Egr-1.0
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Fig. 3. Elevated expression of PLD suppresses PMA-induced trans-
activation of a reporter with Egr-1 response elements. Vector, PLD1 or
PLD2-overexpressed cells were transfected with pEBS14luc for 24 h
and then treated with 100 nM PMA for 12 h. Luciferase activity was
assayed as described in Section 2. Results show means ± S.D. of three
independent experiments.
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Fig. 4. PLD activity is involved in the suppression of PMA-induced Egr-1 ex
and the indicated expression vectors, treated with 100 nM of PMA for 12 h an
independent experiments. (B) Glioma cells were pretreated with 0.5% 1-butan
The lysates were immunodetected with the indicated antibody. The levels
pretreated with the indicated concentration of 1-propranolol (C) and PA (D
immunodetected with anti-Egr-1 or b-tubulin antibody. The data shown are3.3. PLD activity is involved in the suppression of PMA-induced
Egr-1expression
We examined whether PLD activity aﬀects PMA-induced
Egr-1 expression. Although PMA-induced Egr-1 promoter
activity was reduced by expression of wild type PLD, PMA
treatment of cells expressing inactive mutants of PLD isozymes
(K898R for PLD1, K758R for PLD2) did not suppress Egr-1
promoter activity (Fig. 4A). Moreover, 1-butanol was used to
block phosphatidic acid production by PLD, by formation of
phosphatidylbutanol through the transphosphatidylation reac-
tion. 1-Butanol did not suppress PMA-induced Egr-1 expres-
sion (Fig. 4B). An identical concentration of 3-butanol, an
inactive analogue for PLD-mediated phosphatidic acid forma-
tion, had no signiﬁcant eﬀect. Furthermore, propranolol, PA
phosphohydrolase inhibitor, suppressed PMA-induced Egr-1
expression (Fig. 4C). Furthermore, dioctanoyl PA signiﬁcantly
inhibited PMA-induced Egr-1 expression (Fig. 4D). These re-
sults demonstrate that PLD activity is importantly involved
in the suppression of PMA-induced Egr-1.
3.4. PLD-induced suppression of Egr-1 by PMA are dependent
upon PI3K
To investigate how PLD suppresses PMA-induced Egr-1
expression, we examined the eﬀect of various inhibitors.
PMA-induced Egr-1 expression was suppressed by MEK
inhibitors (PD98059, U0126), JNK inhibitor (SP60125), and
PKC inhibitor (Go6976), but not inhibitors of p38MAPK
and PI3K (Fig. 5A). These results were also conﬁrmed by
Egr-1 promoter assays (Fig. 5B). Recently, we have reported
that PI3K inhibitor (LY294002) inhibited PLD-suppressed
induction of Egr-1 by etoposide [9]. Therefore, we examined
whether PI3K was involved in the suppression of PMA-in-
duced Egr-1 expression by PLD. PMA-induced Egr-1 expres-
sion was signiﬁcantly increased in a dose-dependent mannerpranolol
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ol or 3-butanol for 30 min and then treated with 100 nM PMA for 1 h.
of Egr-1 were determined by densitometer analysis. The cells were
) for 1 h and treated with PMA for 1 h. The extracted proteins were
representative of three independent experiments.
PMA - + - + + +
LY294002 (μM) 50 10 20 50
Vector
PLD1
PLD2
Vector
PLD1
PLD2
Blot: Egr-1
Blot: β-tubulin
C
D
E
Vector PLD1 PLD2
PMA - - - +++
P-Akt (Ser-473)
Akt
1        1.3      1.6      2.8       1.8       3.3
Vector PLD1 PLD2
0
1
2
3
4
5
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
Vehicle
  PMA
  PMA/LY294002
PD
98
05
9
U
01
26
SB
20
35
80
PMA
PD
16
93
16
SP
60
12
5
LY
29
40
02
β-tubulin
Egr−1
G
o6
97
6
- -
0
2
4
6
8
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 vehicle
 PD98959
 U0126
 SB203580
 PD169316
 SP60125
 LY294002
 Go6976
- PMA
Fig. 5. PLD-induced suppression of Egr-1 is mediated by PI3K pathway. (A) The glioma cells were preincubated with the indicated inhibitors
(10 lM) for 30 min and treated with PMA (100 nM) for 1 h. The cell lysates were analyzed by Western blot. (B) The glioma cells were transfected
with Egr-1 promoter and pretreated with the indicated inhibitors (10 lM) for 30 min and treated with PMA for 12 h. The luciferase activity was
measured. (C) Vector, PLD1or PLD2-overexpressed cells were preincubated with the indicated concentration of LY294002 for 1 h and treated with
PMA for 1 h. The cell lysates were analyzed by Western blot. (D) Vector or PLD-expressed cells were transfected with Egr-1 promoter and
preincubated with LY294002 (20 lM) for 1 h and treated with PMA for 12 h. The luciferase activity was measured. (E) The glioma cells were treated
with PMA for 1 h, and cell lysates were subjected to Western blot analysis using antibodies to phospho-Akt (Ser-473) and Akt. The levels of
phosphorylated Akt were determined by densitometer analysis. The data shown are representative of three independent experiments.
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zymes, but not in vector-transfected cells (Fig. 5C). PMA-in-
duced Egr-1 promoter activity was also increased by
pretreatment with 20 lM LY294002 in PLD-expressed cells,
but not in control cells (Fig. 5D). Moreover, elevated expres-
sion of PLD isozymes stimulated activation of PMA-induced
Akt, downstream of PI3K as assessed by immunoblot analysis
using antibody to phospho-Akt (Ser-473) (Fig. 5E). These re-
sults suggest that PLD-induced suppression of PMA-induced
Egr-1 expression is mediated via PI3K/Akt pathway.4. Discussion
The present study shows that Egr-1 is a novel target for PLD
signaling. We showed that elevated expression and activity of
PLD in glioma cells caused suppression of PMA-induced
Egr-1 expression.PMA is one of the strongest stimuli to induce Egr-1 expres-
sion. Since PMA has been shown to elicit both growth promo-
tion and growth inhibition in diﬀerent cells, it has been
suggested that PKC may participate in negative feedback of
growth. It has been reported that PMA can enhance the growth
inhibitory activity of negative growth factors like transforming
growth factor-b in human prostate cancer cells [14]. Our
preliminary study shows that PLD is overexpressed in human
glioblastoma tissues compared with normal brain tissues. Our
results demonstrate that PMA-induced Egr-1 expression was
inversely correlated to the amount of PLD isozymes expressed,
suggesting that abnormal elevation of PLD expression contrib-
utes to the down-regulation of PMA-induced Egr-1 expression
in glioma cells. Using the experiments including expression of
catalytically inactive mutants of PLD, addition of primary
alcohol, and treatment of propranolol and PA, our ﬁndings
imply that PLD activity is importantly involved in the suppres-
sion of PMA-induced Egr-1 expression.
5944 B.-H. Ahn et al. / FEBS Letters 581 (2007) 5940–5944The identiﬁcation of downstream target genes of Egr-1 will
help us to understand signal-transcription coupling mediated
by Egr-1. Antitumorigenic genes such as p53 [15], PTEN [16]
and nonsteroidal anti-inﬂammatory drug-activated gene-1
[17] were identiﬁed as Egr-1 target genes. Interestingly, PLD-
induced suppression of Egr-1 is sensitive to PI3K inhibitor
and mediated by activation of PI3K pathway. The involve-
ment of PLD in many aspects of cell proliferation and survival
suggests that PLD or target of PLD signaling can prove to be
valuable targets for the therapeutic intervention in cancers.
The identiﬁcation of Egr-1 target genes in glioma cells will
be informative in determining PMA-induced signaling cascade
in these cells downstream of Egr-1. Loss-of-function experi-
ment of Egr-1 are further required to elucidate the exact role
of Egr-1 in PMA-mediated signaling in glioma cells. More-
over, future studies is needed to better understand the mecha-
nism of growth control by Egr-1 via PLD-mediated signaling
pathway in glioma cells.
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